Undecided direction on Korean distribution license for Gilead’s Sovaldi and Harvoni
It is hard to predict where the Korean distribution license of ‘Sovaldi’ and ‘Harvoni,’ Gilead Sciences’ chronic hepatitis C treatments that have drawn interests of both pharmaceutical and distribution industries as large products, will go in the future.
According to the industry concerned, comp...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
